NextCure reported a full year 2025 net loss of $55.8 million, driven by increased R&D spending for its ADC programs. The company ended the year with $41.8 million in cash and expects its runway to extend into the first half of 2027, supporting upcoming clinical readouts for SIM0505 and LNCB74.

NextCure reported a net loss of $11.0 million for the first quarter of 2025, an improvement from the $17.1 million net loss in the prior year's quarter. The decrease in net loss was primarily driven by lower research and development expenses and general and administrative expenses, resulting from the 2024 restructuring.

NextCure, Inc. reported a net loss of $55.7 million for the full year ended December 31, 2024, an improvement from the $62.7 million net loss in 2023. The company completed cohort 1 of its LNCB74 Phase 1 trial and expects its current cash resources to fund operations into the second half of 2026.

NextCure reported a net loss of $11.5 million for the third quarter of 2024, compared to a net loss of $14.3 million for the same period in 2023. The company's cash, cash equivalents, and marketable securities totaled $75.3 million as of September 30, 2024, and are expected to fund operations into the second half of 2026. The company is prioritizing LNCB74 development and seeking a partner for NC410 advancement.

NextCure reported a net loss of $15.4 million for the second quarter of 2024, with cash, cash equivalents, and marketable securities totaling $86.4 million. The company completed enrollment in the ovarian cancer cohort of the NC410 and pembrolizumab combination study and is on track to submit an IND filing for LNCB74 by year-end.

NextCure reported a net loss of $17.1 million for the first quarter of 2024, with cash, cash equivalents, and marketable securities totaling $96.0 million. The company expects these financial resources to fund operations into the second half of 2026.

NextCure is prioritizing its NC410 combo and LNCB74 programs while seeking partnerships for other assets. The company has restructured operations, reducing the workforce by approximately 37%, and expects current cash reserves to fund operations into the second half of 2026.

NextCure reported a net loss of $14.3 million for the third quarter of 2023, compared to a net loss of $18.9 million for the same period in 2022. The company's cash, cash equivalents, and marketable securities totaled $118.2 million as of September 30, 2023, which is expected to fund operations into mid-2025.

NextCure reported cash, cash equivalents, and marketable securities of $130.6 million as of June 30, 2023. Net loss for the quarter ended June 30, 2023, was $17.9 million, consistent with the net loss for the quarter ended June 30, 2022.

NextCure reported its Q1 2023 financial results, including a net loss of $16.1 million, and R&D expenses of $11.6 million. The company's cash, cash equivalents, and marketable securities were $145.5 million as of March 31, 2023, expected to fund operations into mid-2025. Clinical data readouts are expected in 2023 for NC410, NC762, and NC525 programs.

NextCure reported its full year 2022 financial results, highlighting a cash position of approximately $160 million expected to fund operations into mid-2025. The company anticipates data updates on all three clinical programs in 2023.

NextCure reported its third quarter 2022 financial results, highlighted by the discontinuation of the NC318 program and the extension of the cash runway into mid-2025. The company is focusing on advancing its clinical pipeline, including NC410, NC525, and NC762.

NextCure reported its second quarter 2022 financial results, highlighting upcoming clinical data updates for NC318, NC410, and NC762 programs, as well as an IND filing for NC525. The company's cash position was reported as $185.5 million as of June 30, 2022, which is expected to fund operations into the first quarter of 2024.

NextCure reported its first quarter 2022 financial results, highlighting the advancement of its pipeline of four product candidates and anticipating clinical trial updates for NC318, NC410, and NC762, as well as an IND filing for NC525 in the second half of 2022. The company's cash position is expected to fund operations into the first quarter of 2024.

NextCure reported its fourth quarter and full year 2021 financial results. The company's year-end cash position of $219.6 million is expected to fund operations into the first quarter of 2024.

NextCure reported its third quarter 2021 financial results and provided a business update, highlighting upcoming presentations of clinical and biomarker data for its NC318 and NC410 programs at the SITC annual meeting.

NextCure reported second quarter 2021 financial results and provided a business update, highlighting progress across its clinical programs, including enhancements to the NC318 Phase 2 monotherapy trial and the initiation of clinical development for NC762.

NextCure reported its Q4 and full year 2020 financial results, highlighting the advancement of its programs despite the COVID-19 pandemic and the expansion of its pipeline with NC762.